FOLH1 and prostate cancer: The approval of [68Ga]Ga-HBED-CC-PSMA in December 2020 by the FDA for the PET imaging of prostate cancer has catalysed the developed of novel BFCs based on the HBED scaffold, with renewed interest in the once-overlooked chelating platform [25].